Additional Positive Roflumilast Data of RECORD Study at German Congress for Pneumonology.Business Editors/Health/Medical Writers BAD HOMBURG, Germany--(BUSINESS WIRE)--March 12, 2004 ALTANA AG (NYSE NYSE See: New York Stock Exchange : AAA AAA: see American Automobile Association. (Triple A) A common single-cell battery used in a myriad of electronic devices of all variety. Like its double A (AA) cousin, it provides 1.5 volts of DC power. When used in series, the voltage is multiplied. )(FWB (Fixed Wireless Broadband) See fixed wireless. :ALT) reported today that additional efficacy results on Daxas(R) (Roflumilast) in patients suffering from COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) (Chronic Obstructive Pulmonary Disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. , smoker's lung) were presented at a scientific symposium during the 45th Congress of the German Society of Pulmonology pul·mo·nol·o·gy n. The branch of medicine that deals with diseases of the respiratory system. pulmonology The study of the lungs and respiratory function in Frankfurt. This study (RECORD) was enrolled over 1,400 patients in eleven countries. These patients were treated for 24 weeks with either placebo or 250 micrograms or 500 micrograms Roflumilast. Exacerbation rate (acute worsening with requirement of additional treatments) was statistically significant reduced. Exacerbation rate per patient of 1.13 with Placebo decreased to 1.03 with Roflumilast 250 micrograms and to 0.75 with Roflumilast 500 micrograms. Contrary to the original planning to present the data in May for the first time they have been made public to the medical experts today. Roflumilast is a selective phosphodiesterase-4-inhibitor for the treatment of COPD and asthma. Roflumilast is being developed worldwide - with the exception of Japan - together with Pfizer Inc. Our partner in Japan is Tanabe Seiyaku Co., Ltd. In February 2004 Roflumilast was submitted for European approval to the European Agency for the Evaluation of Medicinal Products (EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. ). This press release contains forward-looking statements, i.e., current estimates or expectations of future events or future results. The forward-looking statements appearing in this press release include information on the presentation of study results. These statements are based on beliefs of ALTANA's management and information currently available to ALTANA. Many factors that ALTANA is unable to predict with accuracy could cause ALTANA's actual performance to be materially different from the one that may be expressed or implied by such forward-looking statements. Forward-looking statements speak only as of the date they are made. ALTANA does not intend, and does not assume any obligation, to update forward-looking statements to reflect facts, circumstances or events that have occurred or changed after such statements have been made. This press release is also available on the Internet at www.altana.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion